Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension레닌-안지오텐신계 억제제는 고혈압 환자의 임상 결과를 개선합니다.Letter Published on 2020-03-312022-09-06 Journal: Emerging Microbes & Infections [Category] Communicable Disease, COVID-19, MERS, SARS, [키워드] ACEi ACEIs addition angiotensin Angiotensin II angiotensin II type 1 receptor blockers angiotensin II type1 receptor blockers angiotensin-converting enzyme inhibitor angiotensin-converting enzyme inhibitors antihypertensive drugs ARB ARBs benefit blocker CD3 CD8 T cell Clinical outcome clinical outcomes contribute Coronavirus infection coronavirus infection disease COVID-19 COVID-19 patient COVID-19 patients dysfunction enrolled evaluate the effect Evidence hypertension IL-6 IMPROVE inhibitor Patient patients Peripheral blood RAS RAS inhibitors receiving receptor Receptor Blockers Renin renin-angiotensin system severe disease Support T cell therapy Viral Viral load [DOI] 10.1080/22221751.2020.1746200 PMC 바로가기 [Article Type] Letter
Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 InfectionCommentary Published on 2020-03-202022-10-29 Journal: mBio [Category] Coronavirus, MERS, SARS, [키워드] ACE2 acute respiratory disease angiotensin ARDS blocker clinical COVID-19 death determine drug combination Endothelial dysfunction generic drugs host response treatment Infection Patient PROTECT receptor risk Severe COVID-19 Infection syndrome tissue treat treating Trial with COVID-19 [DOI] 10.1128/mBio.00398-20 PMC 바로가기 [Article Type] Commentary
CD200 Receptor Controls Sex-Specific TLR7 Responses to Viral InfectionResearch Article Published on 2012-05-172022-10-29 Journal: PLoS Pathogens [Category] Coronavirus, [키워드] absence Activation administration anti-viral response Author blocker Cancer CD200 clearance clinical trial Control dependent on determine determined different disease disease symptom ENhance Factor female female patient females Host humans Hypothesis IFN immune immune inhibitory immune response immune system immunological impair implication IMPROVE in vitro in vivo Infection influenza A virus Influenza virus inhibit inhibitory inhibitory signal lack Ligand lung MHV mice microbial infection mouse hepatitis neutrophil observé outcome overactive pathogen pathology pathway predict Prevent provided receptor receptors Release reported response Sex Sex difference Signaling supported suppresse therapeutic targeting therapeutic use threshold TLR7 Treatment Type I IFN type I interferon viral clearance viral infection virus virus infection [DOI] 10.1371/journal.ppat.1002710 PMC 바로가기 [Article Type] Research Article